Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Receivables (2021 - 2025)

Historic Receivables for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Q3 2025 value amounting to $33.0 million.

  • Rhythm Pharmaceuticals' Receivables rose 7110.74% to $33.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.0 million, marking a year-over-year increase of 7110.74%. This contributed to the annual value of $18.5 million for FY2024, which is 2451.74% up from last year.
  • Rhythm Pharmaceuticals' Receivables amounted to $33.0 million in Q3 2025, which was up 7110.74% from $26.1 million recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Receivables peaked at $33.0 million during Q3 2025, and registered a low of $862000.0 during Q1 2022.
  • In the last 5 years, Rhythm Pharmaceuticals' Receivables had a median value of $14.6 million in 2023 and averaged $13.2 million.
  • Per our database at Business Quant, Rhythm Pharmaceuticals' Receivables skyrocketed by 84164.73% in 2023 and then soared by 2129.98% in 2025.
  • Rhythm Pharmaceuticals' Receivables (Quarter) stood at $1.0 million in 2021, then soared by 507.22% to $6.2 million in 2022, then surged by 138.87% to $14.9 million in 2023, then grew by 24.52% to $18.5 million in 2024, then soared by 78.45% to $33.0 million in 2025.
  • Its last three reported values are $33.0 million in Q3 2025, $26.1 million for Q2 2025, and $17.8 million during Q1 2025.